ACHE and Alzheimer disease: Currently FDA-approved anti-AD drugs are limited to acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists based on the link between cholinergic dysfunction, excitotoxicity and severity of this disease7.